Cancer impacts the United States in ways that are both measurable and uneven, from survival gaps by stage to a 7.3% clinical trial accrual rate in 2022. A $156.6B price tag in 2022 for direct medical costs sits alongside stark outcomes such as 31% 5 year survival for distant stage breast cancer and 3% for distant stage pancreatic cancer. Here is what the latest national data reveal about who is most affected, what care reaches patients, and where prevention and early detection can change the odds.
Key Takeaways
- 20.9% 5-year relative survival rate for all cancers combined is reported for adults diagnosed 2013–2019
- Median 5-year survival for localized stage colorectal cancer is 90% (for adults diagnosed 2010–2016)
- Median 5-year survival for regional stage prostate cancer is 97% (for adults diagnosed 2010–2016)
- 30% of men and women were projected to die from cancer (excluding non-melanoma skin cancer) at some point in their lifetime (estimated by SEER Cancer Statistics Review)
- 14% of all deaths in the United States were attributed to cancer (2019)
- 83% of lung cancer cases are diagnosed at a late stage, and early detection can improve outcomes (SEER stat fact for lung late-stage proportion)
- $0.8 billion federal government spending on colorectal cancer screening promotion programs in 2023 (CDC grant total)
- Cancer remains the most expensive disease category in the United States with an estimated $156.6B direct medical costs in 2022 (ACS estimate)
- Over $140 billion in direct medical costs for cancer were estimated for 2020 in the United States
- In 2021, total spending on prescription oncology drugs in the United States was $56.1 billion
- $6.7 billion in spending on surgical oncology procedures was estimated for 2022 (ACS cost model)
- 1.2 million new cancer diagnoses were estimated for 2024 among men in the United States (ACS projections)
- 21.1% of adults with cancer reported being uninsured at some point in 2018 (NHIS-based estimate)
- In 2023, there were 664,000 oncology workers in the US (BLS/industry estimates)
- The US had 23,000 hematologists/oncologists active in 2022 (AAMC)
Despite improved survival for some cancers, lung and metastatic disease remain major challenges while cancer costs and deaths stay high.
Survival & Staging
120.9% 5-year relative survival rate for all cancers combined is reported for adults diagnosed 2013–2019[1]
Single source
2Median 5-year survival for localized stage colorectal cancer is 90% (for adults diagnosed 2010–2016)[2]
Single source
3Median 5-year survival for regional stage prostate cancer is 97% (for adults diagnosed 2010–2016)[3]
Verified
4Median 5-year survival for distant stage breast cancer is 31% (for adults diagnosed 2010–2016)[4]
Verified
5Median 5-year survival for localized stage melanoma of the skin is 99% (for adults diagnosed 2010–2016)[5]
Verified
6Estimated 5-year relative survival rate for leukemia is 65% for adults diagnosed 2013–2019[6]
Verified
7Median 5-year survival for distant stage kidney and renal pelvis cancer is 14% (for adults diagnosed 2010–2016)[7]
Verified
8Median 5-year survival for distant stage pancreatic cancer is 3% (for adults diagnosed 2010–2016)[8]
Directional
Survival & Staging Interpretation
Across these Survival and Staging figures, survival drops sharply once cancers are diagnosed at distant stages, with distant breast cancer at 31%, distant kidney and renal pelvis cancer at 14%, and distant pancreatic cancer just 3%, compared with much higher localized or regional outcomes like localized colorectal cancer at 90% and regional prostate cancer at 97%.
Incidence & Mortality
130% of men and women were projected to die from cancer (excluding non-melanoma skin cancer) at some point in their lifetime (estimated by SEER Cancer Statistics Review)[9]
Single source
214% of all deaths in the United States were attributed to cancer (2019)[10]
Single source
Incidence & Mortality Interpretation
From an Incidence and Mortality perspective, cancer is projected to claim about 30% of men and women over their lifetimes and account for 14% of all U.S. deaths in 2019, showing a major and lasting health impact.
Screening & Prevention
183% of lung cancer cases are diagnosed at a late stage, and early detection can improve outcomes (SEER stat fact for lung late-stage proportion)[11]
Verified
2$0.8 billion federal government spending on colorectal cancer screening promotion programs in 2023 (CDC grant total)[12]
Directional
Screening & Prevention Interpretation
With 83% of lung cancer cases diagnosed at a late stage, the screening and prevention message is clear that earlier detection could meaningfully improve outcomes, and the same urgency is reflected in the $0.8 billion the federal government spent in 2023 on promoting colorectal cancer screening programs.
Economic Burden
1Cancer remains the most expensive disease category in the United States with an estimated $156.6B direct medical costs in 2022 (ACS estimate)[13]
Single source
2Over $140 billion in direct medical costs for cancer were estimated for 2020 in the United States[14]
Verified
3In 2021, total spending on prescription oncology drugs in the United States was $56.1 billion[15]
Verified
4$5.5 billion in new cancer drug approvals spending impact was estimated for 2022 (ICES/peer-reviewed summary)[16]
Verified
5$10.5 billion in lost earnings due to cancer were estimated in the United States for 2018[17]
Verified
6$11.6 billion in government spending on cancer was estimated in 2022 (NCI budget summary)[18]
Verified
Economic Burden Interpretation
Cancer is the United States’ most economically burdensome disease, costing about $156.6 billion in direct medical care in 2022 and adding billions more in lost earnings and government spending, underscoring a widening financial strain well beyond just treatment costs.
Treatment & Care Delivery
1$6.7 billion in spending on surgical oncology procedures was estimated for 2022 (ACS cost model)[19]
Verified
21.2 million new cancer diagnoses were estimated for 2024 among men in the United States (ACS projections)[20]
Verified
321.1% of adults with cancer reported being uninsured at some point in 2018 (NHIS-based estimate)[21]
Directional
422% of cancer patients did not receive recommended guideline-concordant care in 2018 (National Cancer Data)[22]
Single source
Treatment & Care Delivery Interpretation
In the Treatment and Care Delivery arena, billions are being spent on surgical oncology while care access and quality gaps persist, with 21.1% of adults with cancer uninsured at some point in 2018 and 22% not receiving guideline-concordant care that same year, even as the projected 1.2 million new male cancer diagnoses in 2024 point to rising demand.
Industry & Workforce
1In 2023, there were 664,000 oncology workers in the US (BLS/industry estimates)[23]
Verified
2The US had 23,000 hematologists/oncologists active in 2022 (AAMC)[24]
Verified
3In 2022, there were 2.1 million registered nurses in the US (BLS)[25]
Verified
4NCI’s SEER program covers about 48% of the US population (SEER coverage statement)[26]
Verified
5NSQIP database includes records for 35 million+ surgical cases (ACS)[27]
Verified
6The US biosimilars market reached $19.3 billion in 2023 (EvaluatePharma, public summary)[28]
Directional
7By 2022, 90% of NCI-designated cancer centers reported using EHR-based data submission (NCI Cancer Center)[29]
Directional
8The overall cancer clinical trial accrual rate in the US was 7.3% in 2022 (clinical trial registry analysis study)[30]
Verified
Industry & Workforce Interpretation
The US cancer workforce and infrastructure appear to be scaling steadily, with 664,000 oncology workers and 2.1 million registered nurses supporting care while trial participation reaches a 7.3% accrual rate in 2022 and most NCI-designated centers move toward EHR-based submissions at 90%.
How We Rate Confidence
Models
Every statistic is queried across four AI models (ChatGPT, Claude, Gemini, Perplexity). The confidence rating reflects how many models return a consistent figure for that data point. Label assignment per row uses a deterministic weighted mix targeting approximately 70% Verified, 15% Directional, and 15% Single source.
Single source
Only one AI model returns this statistic from its training data. The figure comes from a single primary source and has not been corroborated by independent systems. Use with caution; cross-reference before citing.
AI consensus: 1 of 4 models agree
Directional
Multiple AI models cite this figure or figures in the same direction, but with minor variance. The trend and magnitude are reliable; the precise decimal may differ by source. Suitable for directional analysis.
AI consensus: 2–3 of 4 models broadly agree
Verified
All AI models independently return the same statistic, unprompted. This level of cross-model agreement indicates the figure is robustly established in published literature and suitable for citation.
AI consensus: 4 of 4 models fully agree
Models
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Daniel Varga. (2026, February 13). United States Cancer Statistics. Gitnux. https://gitnux.org/united-states-cancer-statistics
MLA
Daniel Varga. "United States Cancer Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/united-states-cancer-statistics.
Chicago
Daniel Varga. 2026. "United States Cancer Statistics." Gitnux. https://gitnux.org/united-states-cancer-statistics.
References
- 1seer.cancer.gov/statfacts/html/all.html
- 2seer.cancer.gov/statfacts/html/colorect.html
- 3seer.cancer.gov/statfacts/html/prost.html
- 4seer.cancer.gov/statfacts/html/breast.html
- 5seer.cancer.gov/statfacts/html/melan.html
- 6seer.cancer.gov/statfacts/html/leuks.html
- 7seer.cancer.gov/statfacts/html/kidrp.html
- 8seer.cancer.gov/statfacts/html/pancreas.html
- 9seer.cancer.gov/csr/1975_2016/results_merged/topic_lifetime_risk.pdf
- 11seer.cancer.gov/statfacts/html/lungb.html
- 26seer.cancer.gov/about/
- 10cdc.gov/nchs/fastats/cancer.htm
- 12cdc.gov/cancer/colorectal/index.htm
- 13acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21720
- 14acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21660
- 19acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21460
- 20acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21474
- 15imshealth.com/-/media/ims/Global/Insights/Pharmaceutical-and-Medical-Research/Oncology-Drug-Spending-Report/oncology_drug_spending_report.pdf
- 16nber.org/system/files/working_papers/w28238/w28238.pdf
- 17jamanetwork.com/journals/jamaoncology/fullarticle/2770823
- 30jamanetwork.com/journals/jamaoncology/fullarticle/2782761
- 18cancer.gov/about-nci/budget
- 29cancer.gov/research/infrastructure/cancer-centers/find
- 21ncbi.nlm.nih.gov/pmc/articles/PMC7288011/
- 22pmc.ncbi.nlm.nih.gov/articles/PMC7423598/
- 23bls.gov/oes/current/oes291022.htm
- 25bls.gov/oes/current/oes291141.htm
- 24aamc.org/data-reports/workforce/interactive-data/active-physicians/workforce-interactive-data
- 27facs.org/quality-programs/acs-nsqip/about/
- 28evaluate.com/vantage/articles/market-access/biosimilars/biosimilars-market-size-2023-19-3-billion